GlobeNewswire Inc.··Johnson Fistel, PllpCompass Therapeutics Stock Plummets After Lead Drug Fails Survival Trial
Compass Therapeutics faces securities investigation after lead drug tovecimig fails overall survival endpoint in COMPANION-002 trial, triggering significant stock losses.
CMPXinvestor lossesstock price decline